AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X

Find Drugs in Development News & Deals for Azithromycin

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
189
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • FOR SUSPENSION;ORAL - EQ 1GM BASE/PACKET
  • FOR SUSPENSION;ORAL - EQ 100MG BASE/5ML
  • FOR SUSPENSION;ORAL - EQ 200MG BASE/5ML
  • TABLET;ORAL - EQ 250MG BASE
  • TABLET;ORAL - EQ 600MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • INJECTABLE;INJECTION - EQ 500MG BASE/VIAL
  • TABLET;ORAL - EQ 500MG BASE
  • FOR SUSPENSION, EXTENDED RELEASE;ORAL - EQ 2GM BASE/BOT

Details:

Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.


Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: The Global Antibiotic Research and Development Partnership

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 17, 2020

Details:

Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.


Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: The Global Antibiotic Research and Development Partnership

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 17, 2020

Aurigene company banner

78th STLE Annual Meeting

Not Confirmed

envelop Contact Supplier

Details:

Zoliflodacin, an antibiotic, is currently undergoing evaluation in late-stage clinical trials with patients for treating gonorrhea, in combination with ceftriaxone/azithromycin.


Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Azithromycin has antibacterial action as it binds to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit.


Lead Product(s): Azithromycin

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Zithromax-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

BPZE1 is the most advanced next generation pertussis vaccine, designed to overcome deficiencies of current vaccines, including limited durability and the inability to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission.


Lead Product(s): Live-attenuated Bordetella Pertussis Vaccine,Azithromycin,Bordetella Pertussis Challenge Strain

Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1

Highest Development Status: Phase IIProduct Type: Vaccine

Partner/Sponsor/Collaborator: Knott Partners

Deal Size: $42.8 million Upfront Cash: Undisclosed

Deal Type: Series D Financing September 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Currently, the company caters to anti-infective and pain-management therapeutic areas and has a pipeline of products to enter into the cardio/diabetic and ortho/gynaecology segments, including Veriaz.


Lead Product(s): Azithromycin

Therapeutic Area: Infections and Infectious Diseases Product Name: Veriaz

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Aurobindo Pharma Limited

Deal Size: $22.5 million Upfront Cash: Undisclosed

Deal Type: Acquisition March 28, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content